Product
QL1706
Aliases
PSB205
12 clinical trials
14 indications
Indication
Metastatic Cervical CancerIndication
Colorectal cancerIndication
CancerIndication
Liver CancerIndication
Advanced Malignant TumorIndication
Hepatocellular CarcinomaIndication
Cervical CancerIndication
Extensive-stage Small-cell Lung CancerIndication
Non-small-cell Lung CancerIndication
Nasopharyngeal CarcinomaIndication
lung cancerIndication
Early Breast CancerIndication
Neoadjuvant TherapyIndication
HR+HER2- Breast CancerClinical trial
An Open-label, Multicenter Phase II Study of QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRCStatus: Recruiting, Estimated PCD: 2024-03-30
Clinical trial
A Phase Ib/II Trial to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of QL1706 or QL1604 Combined With Bevacizumab in Patients With Advanced Hepatocellular CarcinomaStatus: Recruiting, Estimated PCD: 2023-12-30
Clinical trial
A Single-arm, Open, Multicenter Phase II Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Recurrent or Metastatic Cervical CancerStatus: Recruiting, Estimated PCD: 2022-10-30
Clinical trial
A Multicenter, Open Phase 1b Study to Evaluate the Efficacy and Safety of QL1706 Injection in Patients With Advanced Malignant Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2021-12-31
Clinical trial
A Phase II/III, Randomized, Open-label, Multi-center Study to Evaluate the Efficacy and Safety of QL1706 in Combination With Bevacizumab and/or Chemotherapy Versus Sintilimab in Combination With Bevacizumab as First-line Treatment in Patients With Advanced Hepatocellular CarcinomaStatus: Not yet recruiting, Estimated PCD: 2027-09-01
Clinical trial
A Phase 1, Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of QL1706 in Patients With Advanced Malignant TumorStatus: Active (not recruiting), Estimated PCD: 2021-12-31
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate QL1706 Plus Paclitaxel-Cisplatin/Carboplatin With or Without Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical CancerStatus: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
An Open-label Phase 2 Study of QL1706 Plus Carboplatin and Etoposide as First-line Treatment in Patients With Extensive-stage Small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2023-02-01
Clinical trial
A Study of the Safety and Efficacy of QL1706 in Combination With Chemotherapy in First-Line Treatment of Patients With Stage IIIB/C and Stage IV Non-Small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2024-01-01
Clinical trial
A Randomized, Double-blind, Multicenter Phase 3 Clinical Study to Evaluate the Efficacy and Safety of QL1706 in Combination With Chemotherapy in First-line PD-L1 Negative, Locally Advanced or Metastatic Non-small Cell Lung Cancer PatientsStatus: Not yet recruiting, Estimated PCD: 2025-06-23
Clinical trial
A Randomized, Open, Multicenter Phase II/III Trial to Compare the Efficacy and Safety of QL1706 and Carrilizumab Combined With Gemcitabine and Cisplatin in First-line Treatment of Recurrent or Metastatic Nasopharyngeal CarcinomaStatus: Active (not recruiting), Estimated PCD: 2024-12-30
Clinical trial
A Phase II Study of Neoadjuvant QL1706 Plus Chemotherapy in Participants With High-Risk ER+/HER2- Early-Stage Breast Cancer (QUEEN-Neo)Status: Not yet recruiting, Estimated PCD: 2025-11-06